AxoGen (NSDQ:AXGN) posted third-quarter results today that beat the consensus forecast on Wall Street. The Alachua, Fla.-based company reported losses of -$6.1 million, or -14¢, on sales of $28.6 million for the three months ended Sept. 30, 2019, for a bottom-line gain of 26.4% sales growth of 26% compared with Q3 2018. Adjusted to exclude one-time […]
Axogen shares slip on expanded Avance nerve graft study
AxoGen (NSDQ:AXGN) today expanded a study of its Avance graft for treating peripheral nerve damage on a pre-specified statistical analysis, sending its share price down slightly today. Alachua, Fla.-based AxoGen is adding 50 patients and five new centers to the Recon study of Avance, a human allograft designed to bridge severed nerves without a second surgical […]
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves – January 8, 2019
Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The Acton, Mass.-based diabetes-focused medtech company said that McMillan will join the company in February and that Levitz will continue as an advisor for a period following the […]
AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat
AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our […]
Axogen expands addressable market estimate to $2.7B
AxoGen yesterday updated on the company’s nerve repair technology and business strategies for the coming years, saying that it believes that the total addressable market for peripheral nerve repair has grown from earlier estimates of $2.2 billion up to $2.7 billion. The Alachua, Fla.-based company said that the shift in its value was driven by […]
Lumicell taps ex-Accuray COO Londy as CEO | Personnel Moves July 18, 2017
Lumicell said last week it tapped former Accuray (NSDQ:ARAY) chief operating officer Kelly Londy as its new chief exec, with founder W. Lee moving to take the role of prez & chief scientific officer. Prior to holding the COO position at Accuray, Londy has held leadership positions at GE Healthcare (NYSE:GE) and Royal Philips (NYSE:PHG), Lumicell said. “We are […]
CEO Shortall, COO Mojdeh out as Unilife retools | Personnel Moves
Unilife (NSDQ:UNIS) said today that chairman & CEO Alan Shortall and president & COO Ramin Mojdeh are out, effective immediately, as it reorganizes to focus on its revenue-generating programs with existing customers. Unilife, which finally sealed the deal with Amgen last month for an injectable drug delivery system, said it will create a pair of new […]
AxoGen deals 16% stake to Essex Woodlands for $17.1m
AxoGen Inc. (NSDQ:AXGN) said today it sold 4.8 million shares to investment firm Essex Woodlands, reeling in $17.1 million for Axogen and giving Essex Woodlands a 16% stake in the company. The funds from the sale are slated to support market growth and accelerate the company’s entry into new nerve repair markets, including the development and commercialization […]
Clearpath Robotics snags Intuitive Surgical design guru Hanuschik | Personnel Moves
Self-driving vehicle development company Clearpath Robotics said today it picked up Intuitive Surgical‘s (NSDQ:ISRG) director of design & management Mike Hanuschik. Hanuschik led the design and product management for Intuitive Surgical’s flagship da Vinci surgical robot system, the market leading robotic surgery platform. The da Vinci is used in over 500,000 procedures annually, according to […]
AxoGen enrolls first subject in nerve graft study
AxoGen Inc. (NSDQ:AXGN) said yesterday that it enrolled the 1st subject in a clinical trial of its Avance nerve graft. The multicenter, prospective randomized Recon study will compare the Avance graft to nerve tubes currently used for bridging peripheral nerve tissue gaps, the Florida-based regenerative medicine company said. The data from the Recon trial will […]
